Samsung Biologics is a leading global CDMO (Contract Development and Manufacturing Organization) that is driven by innovation and technology. With a focus on enriching human life, they offer end-to-end services for the development and manufacturing of biopharmaceutical products. From cell line development to final aseptic fill/finish and laboratory testing services, they provide seamless solutions to their clients.

Their facilities are designed to meet cGMP (Current Good Manufacturing Practice) standards and can accommodate bioreactors ranging from small to large scales. To meet the increasing demands of biomanufacturing, Samsung Biologics has launched Plant 4, the world's largest manufacturing facility at a single site, with a total capacity of 604KL. They have also announced plans to construct Plant 5, which will be operational in 2025.

As a trusted and sustainable partner, Samsung Biologics ensures on-time, in-full delivery of high-quality products through their flexible manufacturing solutions and operational excellence. With a commitment to bettering human life, they strive to bring new hope and possibilities for the future through their dedication and passion for biomedicines